This company has shut down. OncoVerity is no longer operating — its last tracked round was a Series A in 2024.
Explore the Startup GraveyardOncoVerity focuses on optimizing and advancing the development of cusatuzumab, a novel anti-CD70 antibody.
OncoVerity has raised $14.0M in total funding. The most recent round was Series A. The last funding was announced in November 2024.
OncoVerity's investors include argenx, RefinedScience, University License Equity Holdings.
OncoVerity is headquartered in Aurora, United States.
OncoVerity focuses on optimizing and advancing the development of cusatuzumab, a novel anti-CD70 antibody.
OncoVerity is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OncoVerity — Funding & Investors." VCBacked, November 21, 2024, https://www.vcbacked.co/company/oncoverity. Accessed September 30, 2026.
VCBacked. (2024). OncoVerity — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/oncoverity
{{cite web |title=OncoVerity — Funding & Investors |url=https://www.vcbacked.co/company/oncoverity |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated